Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug

(2015) Xianzhou Song et al.   PLoS One

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

(2013) M. Weiner et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Co-targeting estrogen receptor and HER2 pathways in breast cancer

(2013) Arjun Mehta et al.   BREAST

AIB1 Cooperates with ERα to Promote Epithelial Mesenchymal Transition in Breast Cancer through SNAI1 Activation

(2013) Miao Wang et al.   PLoS One

The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor

(2012) S. Alkner et al.   ANNALS OF ONCOLOGY

Prediction of outcome after diagnosis of metachronous contralateral breast cancer

(2011) Sara Alkner et al.   BMC CANCER

Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells

(2011) Zhang-Zhi Hu et al.   PLoS One

Paired distribution of molecular subtypes in bilateral breast carcinomas

(2011) Hege G. Russnes et al.   Cancer Genetics

Estrogen-Dependent and Estrogen-Independent Mechanisms Contribute to AIB1-Mediated Tumor Formation

(2010) M. I. Torres-Arzayus et al.   CANCER RESEARCH

Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer

(2009) B. Banelli et al.   ANNALS OF ONCOLOGY

AIB1 is a predictive factor for tamoxifen response in premenopausal women

(2009) S. Alkner et al.   ANNALS OF ONCOLOGY

AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells

(2009) Wenhui Zhao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence

(2009) A. M. Redmond et al.   CLINICAL CANCER RESEARCH

Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen

(2008) Antoni Hurtado et al.   NATURE

Role of AIB1 for Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells

(2008) Qingbo Su et al.   ONCOLOGY

Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study

(2007) Lisbeth Bertelsen et al.   JNCI-Journal of the National Cancer Institute